Advaxis Inc. (NASDAQ: ADXS) Starts Presentation at The LD 500
Advaxis Inc. (NASDAQ: ADXS) is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (Lm) antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy, as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants and simultaneously reduce tumor protection in the tumor microenvironment to enable…







